Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2011-07-12
2011-07-12
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S171000
Reexamination Certificate
active
07977388
ABSTRACT:
Use of idebenone for the preparation of a medicament for the treating of a muscular dystrophy in particular for treating and/or preventing weakness and/or loss of skeletal muscle tissue and/or cardiomyopathy associated with a muscular dystrophy.
REFERENCES:
patent: 6133322 (2000-10-01), Rustin et al.
patent: 2003/0013772 (2003-01-01), Murphy et al.
patent: 2004/0081961 (2004-04-01), Delegeane et al.
patent: WO 2006/007910 (2006-01-01), None
McNally, Elizabeth, et al, “Cardiomyopathy in Muscular Dystrophy Workshop Sep. 28-30, 2003, Tuscon, Arizona,” Neuromuscular Disorders, vol. 14, pp. 442-448 (2004).
Silversides, Candice, et al, “Effects of Deflazacort on the Left Ventricular Function in Patients With Duchenne Muscular Dystrophy,” The American College of Cardiology, vol. 91, pp. 769-772 (Mar. 2003).
International Search Report for PCT/EP2006/002536 dated Jul. 20, 2006.
Mealy et al., “Annual Update 2004/2005—Treatment of Neurological Disorders,” Drugs of the Future, vol. 30, No. 11, 2005, pp. 1107-1200.
Osako, “The Effects of Idebenone and Glycyrrhizin onmdxMouse Muscle,” Journal of the Medical Society of Toho University, vol. 46, No. 1, 1999, pp. 72-80 (English abstract).
Kurihara et al., “Electrical myotonia and cataract in X-linked muscular dystrophy (mdx) mouse,” Journal of the Neurological Sciences, vol. 99, No. 1, Oct. 1990, pp. 83-92.
English translation of First Office Action (Notice of Reasons for Rejection) received in counterpart Japanese Patent Application No. 2008-502302 dated Feb. 7, 2011 (2 pages).
Ministry of Welfare, the Japanese Government (by trust money on mental
eurological disorder research), article entitled, “Research on the pathology and treatment of muscular dystrophy and related diseases,” Takagi Group, Research Report of 1995, Mar. 1996 (in Japanese, with partial English translation) (8 pages).
Buyse Gunnar
Meier Thomas
Henley, III Raymond J
Kilyk & Bowersox P.L.L.C.
Santhera Pharmaceuticals (Schweiz) AG
LandOfFree
Quinone derivative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinone derivative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinone derivative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678619